Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25474461 | 1.00 | HSD17B2 (0.37) | HSD17B2SLC6A4SLC6A3SLC6A2ACHE | |
| SCHEMBL25474388 | 0.83 | SLC6A2 (0.43) | HSD17B2SLC6A4SLC6A3SLC6A2ACHE | |
| SCHEMBL25474391 | 0.83 | SLC6A2 (0.43) | HSD17B2SLC6A4SLC6A3SLC6A2ACHE | |
| SCHEMBL9413697 | 0.77 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL25474510 | 0.76 | ACP3 (0.38) | HSD17B2SLC6A4SLC6A3SLC6A2ACP3 | |
| SCHEMBL7453051 | 0.76 | PKM (0.40) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL25474509 | 0.74 | SLC6A2 (0.37) | HSD17B2SLC6A4SLC6A3SLC6A2AOC3 | |
| SCHEMBL18501542 | 0.74 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL25474463 | 0.74 | ACP3 (0.39) | HSD17B2SLC6A4SLC6A3SLC6A2AOC3 | |
| SCHEMBL18501544 | 0.74 | FFAR1 (0.43) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | HSD17B2 895/4885SLC6A4 596/4885SLC6A3 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.